MK-0429 is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting integrin. It targets the α5β1, αvβ1, αvβ3, and αvβ5.
Molecular Weight
439.51
Molecular Formula
C23H29N5O4
Targets
α5β1: 12.2 nM (IC50, inhibition of fibronectin-binding); αvβ1: 1.6 nM (IC50, inhibition of fibronectin-binding ); αvβ3: 2.8 nM (IC50, inhibition of vitronectin-binding); αvβ5: 0.1 nM (IC50, inhibition of vitronectin-binding)
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
MK-0429 is a cytoskeletal signaling inhibitor that can be used for its effects on tumor growth, angiogenesis, and bone resorption.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
